Asian industry set to get new QMS auditing and post-market safety guidelines
This article was originally published in Clinica
Executive Summary
The Asian Harmonization Working Party (AHWP) has set out new guidelines which it wants its member countries to use when auditing the quality management systems (QMS) of medical device manufacturers. They were formally presented for endorsement at its annual conference last week, together with another two documents that aim to establish uniform standards for overseeing the safety of marketed medical devices and the reporting of adverse events.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.